Jeff Pregenzer
Plus aucun poste en cours
Profil
Jeff Pregenzer is Senior Research Scientist of CeeTox, Inc. He has 15 years of experience as a Senior Research Associate in the Central Nervous Systems Diseases Research Unit of the Upjohn Co. and Pharmacia Corp.
Mr. Pregenzer joined Dr. McKim's Predictive Toxicology Unit at Pharmacia in 1999.
He has over 20 years of experience in molecular, biochemical, and cellular procedures.
Mr. Pregenzer received a BS degree from Albion College in 1982 and an MS degree from Western Michigan University in 1985.
Anciens postes connus de Jeff Pregenzer
| Sociétés | Poste | Fin |
|---|---|---|
| The Upjohn Co. | Corporate Officer/Principal | - |
Pharmacia Corp.
 Pharmacia Corp. Pharmaceuticals: MajorHealth Technology Pharmacia Corp. developed, manufactured and marketed pharmaceutical products. Prescription pharmaceuticals included general therapeutics, ophthalmology and hospital products including oncology and diversified therapeutics. It also operated in consumer health care, animal health, diagnostics and contract manufacturing and bulk pharmaceutical chemicals. The customers of the group were pharmacies, hospitals, chain warehouses, governments, physicians, wholesalers and other distributors. It was headquartered in Peapack, NJ. | Corporate Officer/Principal | - |
Lab Pathways, Inc.
 Lab Pathways, Inc. Miscellaneous Commercial ServicesCommercial Services Lab Pathways, Inc. was founded in July of 2003 as a Contract Research Organization focused on in vitro toxicity screening of potential drug candidates and chemicals. CeeTox resides in 4,200-square-feet of state-of-the-art laboratory space in the Southwest Michigan Innovation Center (SMIC), a $13 million facility that serves as an incubator for new biotech companies in the Southwest Michigan area. In 2010, CeeTox purchased certain assets formerly owned by ADMETRx Inc. This asset purchase increases CeeTox's existing ADME capabilities and is yet another step in its strategy to expand its range of in vitro service offerings. The scientists at CeeTox have a collective experience of more than 100 years in areas of cell culture, biochemistry, and toxicology. The team has analyzed more than 4,000 new chemical entities and has repeatedly demonstrated the value of early in vitro toxicity data in the drug discovery process. | Directeur Technique/Scientifique/R&D | - |
Formation de Jeff Pregenzer
| Albion College | Undergraduate Degree |
| University of Michigan | Graduate Degree |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Entreprise privées | 3 |
|---|---|
| The Upjohn Co. | Health Technology |
Pharmacia Corp.
Pharmacia Corp. Pharmaceuticals: MajorHealth Technology Pharmacia Corp. developed, manufactured and marketed pharmaceutical products. Prescription pharmaceuticals included general therapeutics, ophthalmology and hospital products including oncology and diversified therapeutics. It also operated in consumer health care, animal health, diagnostics and contract manufacturing and bulk pharmaceutical chemicals. The customers of the group were pharmacies, hospitals, chain warehouses, governments, physicians, wholesalers and other distributors. It was headquartered in Peapack, NJ. | Health Technology |
Lab Pathways, Inc.
Lab Pathways, Inc. Miscellaneous Commercial ServicesCommercial Services Lab Pathways, Inc. was founded in July of 2003 as a Contract Research Organization focused on in vitro toxicity screening of potential drug candidates and chemicals. CeeTox resides in 4,200-square-feet of state-of-the-art laboratory space in the Southwest Michigan Innovation Center (SMIC), a $13 million facility that serves as an incubator for new biotech companies in the Southwest Michigan area. In 2010, CeeTox purchased certain assets formerly owned by ADMETRx Inc. This asset purchase increases CeeTox's existing ADME capabilities and is yet another step in its strategy to expand its range of in vitro service offerings. The scientists at CeeTox have a collective experience of more than 100 years in areas of cell culture, biochemistry, and toxicology. The team has analyzed more than 4,000 new chemical entities and has repeatedly demonstrated the value of early in vitro toxicity data in the drug discovery process. | Commercial Services |
